ipamorelin cjc vs tesamorelin Ipamorelin: Key Differences, Benefits, and Uses Tesamorelin vs CJC-1295: Research Compared

[6] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels

Its compounding status has been unsettled and repeatedly revised: the FDA placed ipamorelin (with CJC-1295) on the Category 2 "do not compound" bulks list in October 2023 citing insufficient safety data

However, it is essential for the research

Interestingly, GFR remained increased even 14 days after cessation of rhIGF-1 therapy compared to placebo-treated controls, suggesting that rhIGF-1 resulted in renal hypertrophy, since the hemodynamic effects should have worn off within 14 days of cessation